TVM Life Science Ventures VII L.P.

CIK 1640880 · last filed 2017-09-27

TVM Life Science Ventures VII L.P. is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing, for ACERW, was dated Sep 27, 2017. Across all open-market trades the lifetime net is +$10.0M, making them a net buyer over the disclosed history. The firm reports its address in Montreal, A8. 8 SEC filings were submitted jointly with Luc Marengere.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

3

Lifetime Open-Market Net

$10.00M

Filer Profile

Reported Address
204, RUE NOTRE-DAME OUEST, BUREAU 350
MONTREAL, A8 H2Y 1T3
Phone
(514) 931-4111
State of Incorporation
XX
Related Filers
Luc Marengere — 8 joint filings, latest 2018-08-22
Hubert Birner — 4 joint filings, latest 2018-08-22
Stefan Fischer — 4 joint filings, latest 2018-08-22
Gary Leatt — 4 joint filings, latest 2018-08-22
HELMUT SCHUHSLER — 4 joint filings, latest 2018-08-22
TVM Life Science Ventures VI GmbH & Co KG — 3 joint filings, latest 2018-01-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Acer Therapeutics Inc. (ACERW) Delisted Director 227,485 — — $0 1 2017-09-27
CoLucid Pharmaceuticals, Inc. (CLCD) Delisted 10%+ Owner 0 — — $10.00M 2 2017-03-01

Recent Filings

3 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2017-09-27 Acer Therapeutics Inc. (ACERW) Delisted Other (J) +18,575,784 $0 EDGAR
2017-03-01 CoLucid Pharmaceuticals, Inc. (CLCD) Delisted Mixed −3,090,772 -$143.72M EDGAR
2015-05-12 CoLucid Pharmaceuticals, Inc. (CLCD) Delisted Mixed +2,990,772 $10.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.